Jul 12, 2017 | Press release
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa. The NIH’s National Institute of Allergy and...
Jun 5, 2017 | Publication
A team of scientists at Scripps Research (Scripps Research) in La Jolla, California has published a study that shows the structure of the viral machinery that Lassa virus uses to enter human cells. The Scripps Research team, led by VHFC researcher Dr. Erica Ollmann...
May 29, 2017 | Publication
Members of the Viral Hemorrhagic Fever Consortium recently published a series of papers that show how Zika virus spread across South America, the Caribbean, and into the United States. The researchers used sequencing technology to collect genomic data that allowed...
May 23, 2017 | Publication
In a Comment article published in the scientific journal Nature, Dr. Erica Ollmann Saphire and colleagues outline how a collaborative strategy among researchers can speed up the discovery of treatments for diseases such as Ebola and Zika. Dr Ollmann Saphire shares...
Dec 13, 2016 | Press release
Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, today announced the launch of a new web-based marketplace to further affirm the Company as the global leader in e-commerce for hemorrhagic fever...
Dec 6, 2016 | Press release
Tulane University School of Medicine immunologist Robert Garry has been named one of Foreign Policy magazine’s 100 “Global Thinkers of 2015” for his groundbreaking work developing a rapid Ebola test. Each year Foreign Policy selects the leading global thinkers whose...
Nov 7, 2016 | Publication
Abstract – The magnitude of the 2013-2016 Ebola virus disease (EVD) epidemic enabled an unprecedented number of viral mutations to occur over successive human-to-human transmission events, increasing the probability that adaptation to the human host occurred...
Oct 1, 2016 | Publication
Abstract – Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or...
Aug 22, 2016 | Press release
Opens Advanced Product Development Center in Colorado GERMANTOWN, MD AND DENVER – August 22, 2016 – Zalgen Labs, a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, announced that it has received via transfer the viral...
